We are live on ! Find out more

Viking Therapeutics

VKTX

Market cap $3.68B

31.53 USD

-0.45

1.41%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

31.55

+0.02

0.06%

1 day

-1.41%

5 days

-8.95%

1 month

-5%

3 months

6.41%

6 months

-12.44%

Year to date

-10.98%

1 year

30.88%

5 years

395.75%

10 years

2,288.64%

About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Employees: 65

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 52.9%

Neutral 32.4%

Negative 14.7%

Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss

Viking Therapeutics NASDAQ: VKTX said its obesity drug candidate VK2735 has advanced into Phase 3 development following Phase 2 results that showed approximately 15% weight loss from baseline after 13 weeks at the highest tested dose.

Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss

Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Viking Therapeutics, Inc. (VKTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Baron Global Opportunity Fund Q2 2026 Portfolio Activity

Baron Global Opportunity Fund (the Fund) gained 26.7% (Institutional Shares) during the second quarter, compared to the 14.9% gain for the MSCI ACWI Index (the Index). During the second quarter, we initiated five new positions: Alphabet, Samsung Electronics, Cerebras, DPC Holdings and Innio. We also took advantage of stock price volatility and significant inflows into the Fund to add to many existing positions including Shopify, Nu, NVIDIA, Amazon, GDS, ASML, TSMC, MercadoLibre, Tesla, ServiceTitan, and others.

Baron Global Opportunity Fund Q2 2026 Portfolio Activity

Zacks Investment Research

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?

Zacks Investment Research

Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $32.13, moving 1.74% from the previous trading session.

Viking Therapeutics, Inc. (VKTX) Declines More Than Market: Some Information for Investors

The Motley Fool

Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Axsome Therapeutics has transitioned into a commercial-stage entity with rapidly growing revenue from its central nervous system treatments. Viking Therapeutics remains a clinical-stage player with significant potential in the high-demand obesity and metabolic disease markets.

Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool

Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.

Viking Therapeutics is studying its weight-loss drug candidate in phase 3 trials. Today Eli Lilly and Novo Nordisk dominate the market, but high demand suggests there's room for additional players.

Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There.

Zacks Investment Research

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Viking Therapeutics, Inc. (VKTX) closed at $32.7 in the latest trading session, marking a -2.91% move from the prior day.

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Zacks Investment Research

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

The Motley Fool

Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.

Viking Therapeutics has significant upside potential based on Wall Street targets. VK2735's dual-formulation strategy could differentiate it in a crowded obesity drug market, but it faces major risks, including strong competition and safety concerns with the oral formulation.

Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case.

See News Rankings

Price charts implemented using Lightweight Charts™